US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Curanex Pharmaceuticals

0.4901

-0.0199-3.90%

Post-market: 0.49010.00000.00%19:59 EDT

Volume:207.71K

Turnover:103.54K

Market Cap:13.89M

PE:-2.88

High:0.5284

Open:0.4403

Low:0.4403

Close:0.5100

52wk High:9.18

52wk Low:0.2620

Shares:28.34M

Float Shares:9.09M

Volume Ratio:1.45

T/O Rate:2.28%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.1700

EPS(LYR):-0.1700

ROE:-72.09%

ROA:-43.80%

PB:1.24

PE(LYR):-2.88

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

BRIEF-Curanex Pharmaceuticals Expands Drug Development Pipeline

Curanex Pharmaceuticals Inc - to Focus on Cancer Cachexia as New Core Indication - SEC Filing

THOMSON REUTERS

Curanex targets cancer cachexia in pipeline expansion to broaden therapeutics focus

EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases

Benzinga_recent_news

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CURX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CURX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CURX\",,,,,undefined,":{"symbol":"CURX","market":"US","secType":"STK","nameCN":"Curanex Pharmaceuticals","latestPrice":0.4901,"timestamp":1775160000000,"preClose":0.51,"halted":0,"volume":207712,"hourTrading":{"tag":"盘后","latestPrice":0.4901,"preClose":0.4901,"latestTime":"19:59 EDT","volume":3657,"amount":1781.4401,"timestamp":1775174356091,"change":0,"changeRate":0,"amplitude":0.018133},"delay":0,"changeRate":-0.03901960784313731,"floatShares":9093100,"shares":28340800,"eps":-0.17,"marketStatus":"Closed Good Friday","change":-0.0199,"latestTime":"04-02 16:00:00 EDT","open":0.4403,"high":0.5284,"low":0.4403,"amount":103536.92113408,"amplitude":0.172745,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.17,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"listingDate":1756180800000,"exchange":"NASDAQ","adjPreClose":0.51,"preHourTrading":{"tag":"盘前","latestPrice":0.5047,"preClose":0.51,"latestTime":"09:28 EDT","volume":23683,"amount":12417.832909899998,"timestamp":1775136497323,"change":-0.0053,"changeRate":-0.010392,"amplitude":0.078431},"postHourTrading":{"tag":"盘后","latestPrice":0.4901,"preClose":0.4901,"latestTime":"19:59 EDT","volume":3657,"amount":1781.4401,"timestamp":1775174356091,"change":0,"changeRate":0,"amplitude":0.018133},"volumeRatio":1.445210992598777},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CURX\",,,,,undefined,":{"symbol":"CURX","floatShares":9093100,"roa":"-43.80%","roe":"-72.09%","lyrEps":-0.17,"volumeRatio":1.445210992598777,"shares":28340800,"dividePrice":0,"high":0.5284,"amplitude":0.172745,"preClose":0.51,"low":0.4403,"week52Low":0.262,"pbRate":"1.24","week52High":9.1796,"institutionHeld":0,"latestPrice":0.4901,"eps":-0.17,"divideRate":0,"volume":207712,"delay":0,"ttmEps":-0.17,"open":0.4403,"prevYearClose":0.3306,"prevWeekClose":0.48,"prevMonthClose":0.5113,"prevQuarterClose":0.5113,"fiveDayClose":0.5111,"twentyDayClose":0.3991,"sixtyDayClose":0.3668},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CURX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CURX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CURX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CURX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CURX","date":"2026-04-02","current":-2.882941,"percent":1,"low":-596.14306,"twenty":-47.131746,"median":-10.007184,"eighty":-7.862943,"high":-3.420935,"avg":-62.452266,"sd":129.724677,"marketCap":14453814},"quantilePoints":[{"date":"2025-08-29","current":-343.821021,"twenty":-323.7357,"median":-309.527845,"eighty":-285.033231,"marketCap":144022500},{"date":"2025-09-05","current":-470.352457,"twenty":-397.745937,"median":-357.40162,"eighty":-309.364317,"marketCap":197025000},{"date":"2025-09-12","current":-522.424684,"twenty":-490.623986,"median":-396.156013,"eighty":-317.040593,"marketCap":227272500},{"date":"2025-09-19","current":-81.3514,"twenty":-518.980126,"median":-404.105632,"eighty":-309.03726,"marketCap":35390625},{"date":"2025-09-26","current":-44.190079,"twenty":-502.869283,"median":-357.40162,"eighty":-78.227506,"marketCap":19224187},{"date":"2025-10-03","current":-52.064896,"twenty":-490.623986,"median":-308.710204,"eighty":-52.935681,"marketCap":22650000},{"date":"2025-10-10","current":-48.094947,"twenty":-477.242127,"median":-89.974648,"eighty":-50.763274,"marketCap":20922937},{"date":"2025-10-17","current":-45.236453,"twenty":-457.103092,"median":-68.335176,"eighty":-47.069268,"marketCap":19679395},{"date":"2025-10-24","current":-42.064901,"twenty":-400.925784,"median":-54.241859,"eighty":-44.399354,"marketCap":18299662},{"date":"2025-10-31","current":-42.99649,"twenty":-384.761559,"median":-51.4271,"eighty":-44.033885,"marketCap":18704935},{"date":"2025-11-07","current":-39.915076,"twenty":-365.54998,"median":-50.763274,"eighty":-43.476372,"marketCap":17364415},{"date":"2025-11-14","current":-36.025849,"twenty":-337.125914,"median":-49.550198,"eighty":-42.216596,"marketCap":15672469},{"date":"2025-11-21","current":-9.181804,"twenty":-310.01843,"median":-47.092697,"eighty":-39.195744,"marketCap":11917311},{"date":"2025-11-28","current":-10.640411,"twenty":-308.710204,"median":-46.699426,"eighty":-38.202616,"marketCap":13810477},{"date":"2025-12-05","current":-9.723323,"twenty":-249.517771,"median":-45.236453,"eighty":-36.025849,"marketCap":12620163},{"date":"2025-12-12","current":-10.048671,"twenty":-98.597896,"median":-44.065693,"eighty":-10.640411,"marketCap":13042441},{"date":"2025-12-19","current":-8.629367,"twenty":-81.3514,"median":-43.511146,"eighty":-10.14693,"marketCap":11200288},{"date":"2025-12-26","current":-8.727626,"twenty":-78.227506,"median":-43.029064,"eighty":-9.899316,"marketCap":11327822},{"date":"2026-01-02","current":-7.218797,"twenty":-71.979719,"median":-42.823377,"eighty":-9.635108,"marketCap":9369472},{"date":"2026-01-09","current":-8.085664,"twenty":-66.382742,"median":-40.152859,"eighty":-9.213247,"marketCap":10494602},{"date":"2026-01-16","current":-8.066012,"twenty":-59.883741,"median":-39.074691,"eighty":-8.778721,"marketCap":10469095},{"date":"2026-01-23","current":-7.948101,"twenty":-54.695471,"median":-38.768503,"eighty":-8.563861,"marketCap":10316055},{"date":"2026-01-30","current":-7.314874,"twenty":-52.092225,"median":-38.100754,"eighty":-8.186981,"marketCap":9494172},{"date":"2026-02-06","current":-5.851898,"twenty":-51.809778,"median":-36.025849,"eighty":-8.048981,"marketCap":7595337},{"date":"2026-02-13","current":-6.052785,"twenty":-51.302144,"median":-21.964742,"eighty":-8.00007,"marketCap":7856073},{"date":"2026-02-20","current":-6.982974,"twenty":-51.044424,"median":-10.640411,"eighty":-7.876918,"marketCap":9063391},{"date":"2026-02-27","current":-10.04212,"twenty":-50.763274,"median":-10.175316,"eighty":-7.808791,"marketCap":13033939},{"date":"2026-03-06","current":-8.714526,"twenty":-50.670859,"median":-10.110902,"eighty":-7.819272,"marketCap":11310818},{"date":"2026-03-13","current":-8.402278,"twenty":-50.150997,"median":-10.04212,"eighty":-7.828006,"marketCap":10905544},{"date":"2026-03-20","current":-9.280064,"twenty":-49.259148,"median":-9.875079,"eighty":-7.876918,"marketCap":12044845},{"date":"2026-03-27","current":-11.160095,"twenty":-47.902307,"median":-10.007184,"eighty":-7.935873,"marketCap":14484989},{"date":"2026-04-02","current":-3.420935,"twenty":-47.131746,"median":-10.007184,"eighty":-7.862943,"marketCap":14453814}],"updateTime":1775243549501},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CURX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2624502516","title":"BRIEF-Curanex Pharmaceuticals Expands Drug Development Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2624502516","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624502516?lang=en_us&edition=fundamental","pubTime":"2026-04-02 21:49","pubTimestamp":1775137796,"startTime":"0","endTime":"0","summary":"BRIEF-Curanex Pharmaceuticals Expands Drug Development Pipeline April 2  - Curanex Pharmaceuticals Inc CURX.O:CURANEX PHARMACEUTICALS INC - EXPANDS DRUG DEVELOPMENT PIPELINE - SEC FILINGCURANEX PHARMACEUTICALS INC - TO FOCUS ON CANCER CACHEXIA AS NEW CORE INDICATION - SEC FILINGSource text: [ID:n0001493152-26-014815]Further company coverage: CURX.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0UX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624509316","title":"Curanex Pharmaceuticals Inc - to Focus on Cancer Cachexia as New Core Indication - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2624509316","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624509316?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:22","pubTimestamp":1775132532,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nFWN40L0UX:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624064915","title":"Curanex targets cancer cachexia in pipeline expansion to broaden therapeutics focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2624064915","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624064915?lang=en_us&edition=fundamental","pubTime":"2026-04-02 20:08","pubTimestamp":1775131687,"startTime":"0","endTime":"0","summary":"Curanex broadened pipeline strategy to add cancer cachexia as a new core indication, expanding beyond its existing focus areas.Company plans to pursue drug development in cancer cachexia, targeting an area with no approved therapies in US.Curanex expects cancer cachexia to be a long-term commercial growth driver, with global market estimated at USD 2.54 billion in 2024.Lead program Phyto-N remains on track for a planned IND filing in ulcerative colitis while management evaluates additional development opportunities tied to inflammation and metabolic dysfunction.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDLVHGWK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","NDAQ","LU0314104364.USD","BK4007","IE00BN0W2W23.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","CURX","BK4588","LU2210150020.SGD","SG9999014013.SGD","BK4112","IE00BN0W2T93.GBP","BK4585","LU2095319765.USD","SG9999014039.USD","IE00BKPKM429.USD","SG9999014021.USD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624506628","title":"EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2624506628","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624506628?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:53","pubTimestamp":1775130780,"startTime":"0","endTime":"0","summary":"Curanex expands pipeline with cancer cachexia, advances Phyto-N toward IND, and reports preclinical safety data.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/04/02/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/04/02/Cancer---Heart-Shape-To-Represent-Medica.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/biotech/26/04/51621768/exclusive-curanex-pipeline-expansion-signals-push-beyond-inflammation-metabolic-diseases","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/biotech/26/04/51621768/exclusive-curanex-pipeline-expansion-signals-push-beyond-inflammation-metabolic-diseases","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["IND","CURX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":7,"pageCount":1,"totalSize":26,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CURX\",params:#limit:6,delay:false,,,undefined,":[]}}